Ascentage Pharma Group International
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a AAPG research report →
Range $40 – $51
Price Chart
About the company
Ascentage Pharma Group International is a clinical-stage biopharmaceutical firm dedicated to discovering and developing innovative therapies for various cancers, chronic hepatitis B virus (HBV), and age-related conditions. Its operations are concentrated across the United States and Mainland China. Ascentage Pharma's flagship therapeutic candidate, HQP1351 (Olverembatinib), is a BCR-ABL inhibitor specifically designed to target BCR-ABL mutants, including those carrying the T315I mutation.
- CEO
- Dajun Yang
- IPO
- 2025
- Employees
- 767
- HQ
- Suzhou, JS, CN
Get TickerSpark's AI analysis on AAPG
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.11B
- P/E
- -5.10
- Fwd P/E
- 3.58
- PEG
- 0.50
- P/S
- 11.71
- P/B
- 13.32
- EV/EBITDA
- -5.85
- Div Yield
- 0.00%
- Gross Margin
- 81.56%
- Op Margin
- -218.70%
- Net Margin
- -228.60%
- ROE
- -153.78%
- ROIC
- -48.87%
Latest fiscal year · YoY change
- Revenue
- $558.48M-43.1%
- Gross Profit
- $426.75M-55.2%
- Op Income
- $-1,179,161,166
- Net Income
- $-1,208,909,966-198.2%
- EPS
- $-13.56-153.0%
- OCF Growth
- -954.4%
- FCF Growth
- -785.9%
- 52W High
- $33.09
- 52W Low
- $11.97
- 50D MA
- $15.05
- 200D MA
- $19.37
- Beta
- 0.66
- RSI (14)
- 29
- Avg Volume
- 6.92K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Ascentage said first-half 2026 revenue rose 29% while late-stage global hematology programs stayed on track, with management reaffirming cash runway through 2027 and targeting multiple NDA filings in the second half of next year.· August 20, 2026
- Total revenue was $44.5 million, up 29.3% year over year, driven mainly by $41.6 million of product sales.
- Cash was $279.4 million at June 30, 2026, and management reaffirmed runway through the end of 2027.
- Enrollment is advancing in 9 registrational trials; management said GLORA-2 is complete, GLORA-3 is close, and GLORA-4/POLARIS-1/POLARIS-2 could finish by late this year or early next year.
- The company highlighted lisaftoclax differentiation on daily ramp-up, safety and lower DDI risk, and said China NRDL review is in the final expert stage.
- Management reiterated that potential NDA filings for POLARIS-1/2 and GLORA-4 could come in the second half of next year.
First-half 2026 total revenue was $44.5 million versus $32.6 million in the first half of 2025, up $11.9 million or 29.3% on a constant exchange rate basis. Product sales were $41.6 million. R&D expense was $102.8 million versus $73.8 million a year ago; selling and distribution expense was $33.4 million versus $19.2 million; and administrative expense was $17.5 million versus $13.9 million. Cash and cash equivalents were $279.4 million at June 30, 2026, and management reaffirmed cash runway through 2027. Forward-looking guidance: management said GLORA-4, POLARIS-1 and POLARIS-2 enrollment could complete by late this year or early next year, with potential NDA filings in the second half of next year. They also said the company is on track to expand commercial coverage in China and is taking initial steps to build U.S. commercialization capabilities.
Dajun Yang framed the first half as a step toward building Ascentage into a global, fully integrated hematology-oncology company. He emphasized the company’s two approved products, the breadth of its registrational pipeline, and the strategy of using strong China execution to support global development and eventual commercialization. His tone was confident and expansionary, repeatedly stressing that the company is becoming more “de-risked” as late-stage data mature.
Veet Misra said the first half reflected both continued commercial growth and heavy investment behind the global development portfolio. He cited $44.5 million of revenue, $279.4 million in cash, and reiterated runway through 2027, noting that the company is funding 9 registrational programs while also taking initial steps to build U.S. commercial capabilities. He also said OpEx is near peak because enrollment is in later stages and spending is aligned with major milestones and catalysts.
Analysts focused on lisaftoclax’s China NRDL prospects, trial timing for GLORA and POLARIS, Takeda’s option on olverembatinib, China hospital access, and the BTK degrader APG-3288. Management said lisaftoclax has passed initial NRDL review and is now in final expert review, with confidence in coverage but price still a key variable. For POLARIS-1/2 and GLORA-4, management said enrollment should finish by late this year or early next year, with potential NDA filings in the second half of next year; Takeda’s option is still active, and APG-3288 is not expected to have Phase I data at ASH this year, though management pointed to EHA next year as a possible update.
The bull case from this call is that Ascentage is moving multiple high-value hematology assets toward potential registration while still showing revenue growth and a manageable cash profile. Management argued lisaftoclax and olverembatinib have clear differentiation, and it highlighted several positive efficacy signals across MDS, AML, CML and ALL, plus progress toward NRDL coverage and global commercialization.
The main risks are the high and still-rising operating burn, dependence on successful completion of several late-stage trials, and the fact that commercialization outside China is still early. Management also acknowledged pricing uncertainty in NRDL negotiations, ongoing competitive pressure in CML and Bcl-2 markets, and that APG-3288 and other pipeline assets remain relatively early, with no Phase I data for APG-3288 expected at ASH this year.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 28.4%
- Shares Outstanding
- 23.24M
- Float Shares
- 6.60M
of shares held by institutions
7 13F filers
Buy/sell ratio 10.50. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Point72 Asset Management, L.P. | 13.84K | ▼ 2.21K |
| Arax Advisory Partners | 1.23K | ▲ 1.23K |
| Newedge Advisors, LLC | 455 | ▲ 455 |
| Morgan Stanley | 394 | ▼ 525 |
| Wells Fargo & Company/Mn | 200 | ▲ 200 |
| Nuveen, LLC | 79 | ▲ 79 |
| Eversource Wealth Advisors, LLC | 24 | 0 |
| Caitong International Asset Management Co., Ltd | 1 | 0 |
| Citigroup Inc | 1 | ▲ 1 |
| Blackrock, Inc. | 1 | ▼ 5 |
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 25, 26 | Miyara Faical | other | 0 |
| May 21, 26 | Zhai Yifan | other | 95,575 |
| May 21, 26 | Zhai Yifan | other | 92,746 |
| May 20, 26 | Zhai Yifan | other | 298,195 |
| May 20, 26 | Zhai Yifan | other | 298,194 |
| May 20, 26 | Zhai Yifan | other | 214,999 |
| May 20, 26 | Zhai Yifan | other | 214,988 |
| May 20, 26 | Zhai Yifan | other | 103,365 |
| May 20, 26 | Zhai Yifan | other | 103,364 |
| May 20, 26 | Zhai Yifan | other | 95,575 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our AAPG coverage
Recent articles, reports, and earnings notes.
Want a deeper read on AAPG?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Ascentage Pharma Announces Inclusion of Lisaftoclax in China's 2026 National Reimbursement Drug List and Successful Renewal of Coverage for Olverembatinib
globenewswire.com · Nov 15
Ascentage Pharma to Present Data from Multiple Trials, Including an Oral Presentation of APG-5918 at ASH 2026
globenewswire.com · Nov 4
Ascentage Pharma to Participate in Two Upcoming Investor Conferences in London
globenewswire.com · Nov 3
Ascentage Pharma's Lisaftoclax Granted Breakthrough Therapy Designation in China for Treatment-Naïve CLL/SLL
globenewswire.com · Oct 20
Ascentage Pharma Stock Could More Than Double: Analyst
benzinga.com · Oct 16
Ascentage Pharma Group International (NASDAQ:AAPG) Shares Up 4% – Should You Buy?
defenseworld.net · Oct 12
3 Beaten-Down Biotech Stocks With Triple-Digit Upside and Big Catalysts Ahead
marketbeat.com · Oct 10
3 Small-Cap Stocks With Catalysts That Could Put Them in the Spotlight
marketbeat.com · Oct 5
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
